Lenvatinib plus pembrolizumab (L plus P) vs sunitinib (S) in advanced renal cell carcinoma (aRCC): Patterns of progression and subsequent therapy in the CLEAR trial Meeting Abstract
| Authors: | Grünwald, V.; Motzer, R. J.; Keizman, D.; Bedke, J.; Schmidinger, M.; Staehler, M. D.; Matveev, V. B.; George, S.; Hutson, T. E.; Vaishampayan, U. N.; Merchan, J. R.; Eto, M.; Rha, S. Y.; Waddell, T.; Sabbatini, R.; Barthelemy, P.; Burgents, J. E.; Ren, M.; Brown, I.; Choueiri, T. K. |
| Abstract Title: | Lenvatinib plus pembrolizumab (L plus P) vs sunitinib (S) in advanced renal cell carcinoma (aRCC): Patterns of progression and subsequent therapy in the CLEAR trial |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557401170 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.4524 |
| Notes: | Meeting Abstract: 4524 -- Source: Wos |
